ANEUVO's SCI Therapy Wins Global Award, Heralding New Hope

LOS ANGELES, CA – February 11, 2026 – By Laura Harris

Medical technology firm ANEUVO has received a significant international honor, securing Taiwan’s 22nd National Innovation Award for its ExaStim® neuromodulation system. The award, a prestigious recognition within Asia's burgeoning biomedical sector, highlights a technology poised to redefine rehabilitation for individuals living with spinal cord injuries (SCI) by offering a non-invasive path toward restoring function.

The Los Angeles-based company was celebrated in the International Startup Award track, a category designed to attract global innovators to Taiwan's influential “big health” ecosystem. This accolade is more than just a trophy; it serves as a powerful validation of ANEUVO's mission and a catalyst for its global commercialization strategy, which is already underway in Europe.

A New Era in Spinal Cord Rehabilitation

At the heart of the recognition is the ExaStim® Stimulation System, a non-invasive technology designed to reawaken neural pathways disrupted by injury. For decades, spinal cord injury rehabilitation has faced the immense challenge of bridging the gap between the brain's commands and the body's ability to execute them. ExaStim® tackles this by using transcutaneous electrical spinal stimulation (TSS), a method that avoids the risks and complexities of surgery.

The system works by delivering targeted electrical pulses through a flexible, 16-electrode pad placed on the skin over the spine. These pulses stimulate nerves along the spinal cord and dorsal roots, aiming to re-engage dormant neural circuits and facilitate the restoration of damaged connections. The entire system is portable, rechargeable, and controlled by clinicians via a proprietary app on a standard tablet, allowing for highly personalized stimulation strategies tailored to each patient's unique needs and rehabilitation goals.

This approach stands in stark contrast to more invasive methods, such as epidural stimulation, which requires surgical implantation of a device. By eliminating the need for surgery, ExaStim® significantly lowers the barrier to entry for patients, reduces risks of infection and complications, and opens the door to wider accessibility. Furthermore, its portable design is foundational to the company's vision of extending therapy beyond the clinic and into the home, a critical step for long-term functional improvement and quality of life.

The Gauntlet of Global Validation

ANEUVO's journey to this point has been marked by a deliberate and rigorous process of clinical and regulatory validation. The ExaStim® system is not an unproven concept; it is backed by extensive research, including the company's nationwide, double-blind ASPIRE™ clinical trial. The trial, which enrolled 128 participants across 14 leading U.S. medical centers, was designed to evaluate the therapy's safety and potential to restore arm and hand function in individuals with chronic, traumatic SCI. The results of this foundational study are highly anticipated later this year.

Building on this, ANEUVO has initiated the ASPIRE™ Home Study, an observational trial to assess the safe and effective use of ExaStim® in a real-world home environment. This follow-up study underscores the company's focus on creating a practical, user-friendly therapy that integrates seamlessly into patients' daily lives.

On the regulatory front, ANEUVO has achieved critical milestones on two continents. In the United States, ExaStim® received FDA Breakthrough Device Designation, a program that expedites the review of technologies that could provide more effective treatment for life-threatening or irreversibly debilitating conditions. While the device remains investigational in the U.S., this designation signals the FDA's belief in its potential to address a significant unmet need and provides ANEUVO with a more direct line of communication with the agency as it moves toward eventual market approval.

Across the Atlantic, the company has already cleared the final hurdle. ExaStim® received its CE Mark certification in 2025, confirming its compliance with the European Union's stringent health and safety standards. This certification has unlocked the European market, and ANEUVO has begun a phased rollout, making the technology available to targeted rehabilitation centers across Europe, with plans for broader expansion in 2026.

From Lab to Global Stage: The Business of Breakthroughs

The National Innovation Award is a strategic victory that amplifies ANEUVO's scientific and regulatory achievements. Recognized as a leading platform in Taiwan's biomedical ecosystem, the award is known for its rigorous selection process and focus on commercial viability. ANEUVO’s selection from a pool of nearly 400 submissions, and its subsequent invitation as one of only three companies to present at the award's exclusive pitch showcase, places it firmly in the international medtech spotlight.

This recognition is crucial in the competitive spinal cord injury treatment market, a sector projected to exceed $10 billion within the next decade. While established players and emerging therapies like regenerative medicine and robotics exist, ExaStim® carves out a unique niche by offering a non-invasive, function-focused, and potentially home-based solution.

The company itself was born from deep academic expertise. Co-founders Dr. Yi-Kai Lo and Dr. Wentai Liu are distinguished neuroengineering experts from UCLA, whose prior work on a successful retinal implant laid the groundwork for ANEUVO's bioelectronic medicine platform. Backed by early-stage venture capital, government grants, and a network of premier clinical partners, the company has methodically built the evidence base for its technology.

“We’re honored to be recognized by the National Innovation Award. This validation reinforces our focus on building a therapy platform that can be integrated into real rehabilitation workflows and scaled responsibly,” said Dr. Yi-Kai Lo, Co-Founder and CEO of ANEUVO, in a recent statement. “Our goal is to bring meaningful, practical innovation to people living with spinal cord injury, and to do it with the quality and evidence patients, clinicians, and partners expect.”

With a clear pathway in Europe, an expedited track with the FDA, and now a major international innovation award, ANEUVO is transitioning from a development-stage company to a commercial force. Its multi-pronged approach of rigorous science, regulatory diligence, and strategic market entry provides a compelling model for medical innovation and offers new hope to a patient community eagerly awaiting more effective and accessible therapies.